Colchicine site inhibitors of microtubule integrity as vascular disrupting agents

Drug Development Research

Volumn 69, Issue 6, 2008, Pages 352-358

  Lee, Ray M ^a   Gewirtz, David A ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Angiogenesis; Colchicine; Microtubules; Tubulin; Vascular targeting

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CD31 ANTIGEN; CD34 ANTIBODY; CELL CYCLE PROTEIN 20; COLCHICINE; COLCHICINE SITE INHIBITOR; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; CREATINE KINASE MB; DENIBULIN; GADOLINIUM PENTETATE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MIVOBULIN ISETHIONATE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ALOPECIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ATAXIA; BLOOD TOXICITY; BONE MARROW TOXICITY; BRADYCARDIA; CANCER PAIN; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL CYCLE ARREST; CHEST TIGHTNESS; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; FATIGUE; GASTROINTESTINAL TOXICITY; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MICROTUBULE; MOLECULAR MODEL; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; QT PROLONGATION; REVIEW; SIDE EFFECT; TACHYCARDIA; THROMBOEMBOLISM; TUMOR VASCULARIZATION; VEIN THROMBOSIS;

EID: 57749113532     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20267     Document Type: Review

References (53)

1. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. 2003. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21:2823-2830.
2. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE. 2006. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498.
3. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. 2004a. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23:2825-2837.
4. Castedo M, Perfettini JL, Roumier T, Yakushijin K, Horne D, Medema R, Kroemer G. 2004b. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23:4353-4361.
5. Chan GK, Jablonski SA, Sudakin V, Hittle JC, Yen TJ. 1999. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J Cell Biol 146:941-954.
6. Collins TS, Hurwitz HI. 2005. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 32:61-68.
7. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, Stambler BS, Remick SC. 2004. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10(Pt 1):96-100.
8. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. 1997. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834.
9. Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. 1996. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest New Drugs 14:131-137.
10. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, et al. 2002. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416.
11. Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD. 2005. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther 4:197-206.
12. Durrant D, Corwin F, Simoni D, Zhao M, Rudek M, Salloum F, Kukreja RC, Fatouros PP, Lee RM. 2008. cis-3, 4′, 5-trimethoxy-3′-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion. Cancer Chemother Pharmacol (in press) [Epub March 2008].
13. Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM. 2006. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 12:4882-4887.
14. Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM. 2008. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 14:1111-1115.
15. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, Sobel A, Knossow M. 2005. Structural basis for the regulation of tubulin by vinblastine. Nature 435:519-522.
16. Gillett ES, Sorger PK. 2001. Tracing the pathway of spindle assembly checkpoint signaling. Dev Cell 1:162-164.
17. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML. 2006. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 12:2834-2840.
18. Hicklin DJ, Ellis LM. 2005. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027.
19. Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, Pettit GR, Chaplin DJ, Edvardsen K. 2003. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 23:1433-1440.
20. Kudelka AP, Hasenburg A, Verschraegen CF, Edwards CL, Meyers CA, Varma D, Freedman RS, Forman A, Conrad CA, Grove W, Grothey A, Kavanagh JJ. 1998. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs 9:405-409.
21. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD. 2004. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 3:661-669.
22. Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE. 2001. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7:1052-1060.
23. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, Tozer GM. 2002. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15:89-98.
24. Morrow CJ, Tighe A, Johnson VL, Scott MI, Ditchfield C, Taylor SS. 2005. Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20. J Cell Sci 118(Pt 16):3639-3652.
25. Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al-Katib AM. 2000. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines. Anticancer Drugs 11:385-392.
26. Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, Wipf P, Hamel E, Gussio R. 2005. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 48:6107-6116.
27. Nicholson B, Lloyd GK, Miller BR, Palladino MA, Kiso Y, Hayashi Y, Neuteboom ST. 2006. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 17:25-31.
28. Patel SR, Burgess MA, Papadopolous NE, Sidhu G, Gray R, Plager C, Jenkins J, Benjamin RS. 1998. Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest New Drugs 16:87-92.
29. Pazdur R, Meyers C, Diaz-Canton E, Abbruzzese JL, Patt Y, Grove W, Ajani J. 1997. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol 20:573-576.
30. Pellegrini F, Budman DR. 2005. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23:264-273.
31. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. 1989. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45:209-211.
32. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. 2004. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428:198-202.
33. Rowinsky EK, Calvo E. 2006. Novel agents that target tubulin and related elements. Semin Oncol 33:421-435.
34. Rowinsky EK, Long GS, Noe DA, Grochow LB, Bowling MK, Sartorius SE, Donehower RC. 1997. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res 3:401-407.
35. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM. 2003. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822.
36. Segreti JA, Polakowski JS, Koch KA, Marsh KC, Bauch JL, Rosenberg SH, Sham HL, Cox BF, Reinhart GA. 2004. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 54:273-281.
37. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS. 2006. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785-1787.
38. Shaked Y, Tang T, Mayer J, Daenen L, Man S, Xu P, Cai SR, Wong J, Arbeit J, Varner J, Voest E, Chaplin D, Harris A, Nathan P, Rustin G, Bertolini P, Link D, Kerbel R. 2008. Molecular mechanisms responsible for vascular disrupting agent-induced acute mobilization and tumor homing of circulating endothelial progenitor cells. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, abstract 5854.
39. Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, Chaplin DJ, Edvardsen K. 2004. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 111:604-610.
40. Shi W, Siemann DW. 2005. Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res 25:3899-3904.
41. Siemann DW, Mercer E, Lepler S, Rojiani AM. 2002. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1-6.
42. Siemann DW, Chaplin DJ, Horsman MR. 2004. Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491-2499.
43. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. 2003. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51:43-52.
44. Sklarin NT, Lathia CD, Benson L, Grove WR, Thomas S, Roca J, Einzig AI, Wiernik PH. 1997. A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Invest New Drugs 15:235-2346.
45. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ. 2003. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428-4438.
46. Thomas JP, Moore T, Kraut EH, Balcerzak SP, Galloway S, Vandre DD. 2002. A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study. Cancer Invest 20:192-198.
47. Thorpe PE. 2004. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427.
48. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ. 1999. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59:1626-1634.
49. Tozer GM, Kanthou C, Baguley BC. 2005. Disrupting tumour blood vessels. Nat Rev Cancer 5:423-435.
50. Vaupel P, Mayer A. 2007. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225-239.
51. Whitehead RP, Unger JM, Flaherty LE, Eckardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK. 2001. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Invest New Drugs 19:239-243.
52. Wildiers H, Ahmed B, Guetens G, De Boeck G, de Bruijn EA, Landuyt W, van Oosterom AT. 2004. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer 40:284-290.
53. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. 2005. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11:6615-6624.